ERBB2 and breast carcinoma: However, due to issues such as drug availability and medical insurance coverage, neoadjuvant anti-HER-2 therapy is still not widely used among Chinese patients with HER-2-positive breast cancer (Li et al., 2018), especially neoadjuvant dual anti-HER-2 therapy.